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Background: EGFRvlll, a constitutively active EGFR deletion driver muta­
tion, is associated with poor long-term survival in glioblastoma (GB). The 
investigational vaccine rindopepimut consists of a peptide sequence 
unique to EGFRvlll conjugated to keyhole limpet hemocyanin (KLH), 
delivered intradermally with GM-CSF. Three phase II studies of rindopep­
imut in newly diagnosed, resected, EGFRvll I+ GB demonstrated encourag­
ing progression-free survival (PFS), overall survival (OS) and safety profile. 
Compassionate use experience suggests that rindopepimut may also 
provide benefit in relapsed GB, particularly with agents such as bevaci­
zumab (BV). Methods: In the Phase II "ReACT" study, BV-naTve pts in l 5' or 
2nd relapse with EGFRvlll+ GB were randomized 1:1 to BV plus double­
blinded injection of rindopepimut or control (KLH). Endpoints: 6-month 
PFS (PFS6; primary), objective response rate (ORR), PFS, OS and safety. 
Results: Accrual is complete (n = 72); study follow-up continues (n = 30). 
Primary rindopepimut toxicity is Grade 1-2 injection site reaction. For 
rindopepimut+BV vs. KLH+BV (per investigator; RANO criteria): PFS6 = 
27% (9/33) vs. 11 % (4/35) (p = 0.048, 1-side chi-square test); ORR =
24% (7/29) vs. 17% (5/30). Central PFS/ORR assessment is underway. 
Median (95% Cl) OS = 12.0 (9. 7, -) vs. 8.8 (6.8, 11.4) months (HR =
0.47 [0.25, 0.911; p = 0.0208), with 8 vs 4 pts progression-free on study. 
OS analyses favor rindopepimut including when adjusted for various 
prognostic factors. Rindopepimut induced robust anti-EGFRvl II titers 
(1:12,800 to 1:6,553,600) in 80% of pts. Rapid anti-EGFRvlll titer 
generation was associated with prolonged OS (HR = 0.47 [0.18, 1.27]; p 
= 0.128) within the rindopepimut arm, and was most frequent in pts with 
KPS 2: 90 (odds ratio = 9.75; p = 0.007). Additional evaluation of 
humoral response quality and HLA typing vs. outcome are underway. In an 
additional cohort of BV-exposed pts (n = 53), four pts experienced 
objective tumor response. Conclusions: These near-final data show that 
rindopepimut induces potent EGFRvl I I-specific immune response and 
tumor regression, and appears to significantly prolong survival when 
administered with BV, in pts with relapsed GB. Clinical trial information: 
NCT01498328. 
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